Free Trial
NASDAQ:CYTT

Cyteir Therapeutics (CYTT) Stock Price, News & Analysis

→ Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad)
Free CYTT Stock Alerts
$3.01
-0.01 (-0.33%)
(As of 03/18/2024)
Compare
Today's Range
$2.92
▼
$3.19
50-Day Range
N/A
52-Week Range
$1.65
▼
$3.19
Volume
551,300 shs
Average Volume
N/A
Market Capitalization
$108.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartEarningsFinancialsSEC FilingsSocial Media

About Cyteir Therapeutics

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

CYTT Stock Price History

CYTT Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com
Receive CYTT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cyteir Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/26/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTT
CUSIP
N/A
CIK
1662244
Web
cyteir.com
Phone
857-285-4140
Fax
N/A
Employees
46
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.94)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-46,060,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-24.88%
Return on Assets
-23.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
21.89
Quick Ratio
21.89

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.13 per share
Price / Book
0.73

Miscellaneous

Outstanding Shares
36,000,000
Free Float
30,814,000
Market Cap
$108.36 million
Optionable
N/A
Beta
0.10
Beginners Guide To Retirement Stocks Cover
Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Joseph S. Zakrzewski (Age 62)
    Independent Investor & Independent Chairman of the Board
    Comp: $81.5k
  • Dr. Markus F. Renschler M.D. (Age 63)
    President, CEO & Director
    Comp: $718.62k
  • Dr. Kevin Mills Ph.D.
    Co-Founder
  • Mr. David G. Gaiero (Age 46)
    CFO & Treasurer

Key Competitors

View All Competitors

CYTT Stock Analysis - Frequently Asked Questions

How have CYTT shares performed in 2024?

Cyteir Therapeutics' stock was trading at $3.01 at the start of the year. Since then, CYTT shares have increased by 0.0% and is now trading at $3.01.
View the best growth stocks for 2024 here.

How do I buy shares of Cyteir Therapeutics?

Shares of CYTT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTT) was last updated on 4/27/2024 by MarketBeat.com Staff

From Our Partners
These AI trades triggered this morning (545% return)
Prosper Trading Academy
Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share
Colonial Metals
He Is Giving Away Bitcoin
Crypto Swap Profits
The A.I. story nobody is telling you (Read ASAP)
TradeSmith
The World's First "$20 Trillion Drug?"
Behind the Markets
Fed launches fourth dollar overhaul
Stansberry Research
Biden out June 13; Kamala won’t replace him?
Paradigm Press
Man Who Predicted 2008: “This Will be Worse.”
Altimetry